Irritants and Allergens: When to Suspect Topical Therapeutic Agents


Questions

  • Q56.1 What types of reactions are included under the term ‘contact dermatitis’? (Pg. 617)

  • Q56.2 What is dermatitis medicamentosa? (Pg. 618)

  • Q56.3 What are some clues that help suggest the presence of contact dermatitis? (Pg. 618)

  • Q56.4 Of the body regions covered in this chapter, which is the least likely to be affected by contact dermatitis? (Pg. 618)

  • Q56.5 What are some of the reasons for the frequency of contact dermatitis affecting the eyelids? (Pg. 619)

  • Q56.6 What is the name of the allergen found in ophthalmic products and frequently reported as a cause of eyelid contact dermatitis? (Pg. 619)

  • Q56.7 What allergen is thought to be the most common cause of photoallergic contact dermatitis? (Pg. 620)

  • Q56.8 Which class of corticosteroids is considered the most ‘hypoallergenic’? (Pg. 621)

  • Q56.9 What allergen is frequently found in over-the-counter products marketed for anogenital use? (Pg. 622)

  • Q56.10 What is the difference between cross-reaction and co-reaction? (Pg. 622)

Abbreviations used in this chapter

ACD

Allergic contact dermatitis

ACDS

American Contact Dermatitis Society

BHA

Butylhydroxyanisole

BHT

Butylhydroxytoluene

ICD

Irritant contact dermatitis

NACDG

North American Contact Dermatitis Group

OTC

Over the counter

PABA

Para-aminobenzoic acid

PG

Propylene glycol

PPD

Paraphenylenediamine

ROAT

Repeat open application test

SPF

Sun protection factor

TRUE

Thin-layer rapid use epicutaneous test

Acknowledgment

The author would like to acknowledge the contributions of Dr. Nico Mousdicas and Matthew J. Zirwas to the previous edition of this chapter.

Introduction

The subject of contact dermatitis tends to polarize dermatologists into one of two camps. There are those who seem to live for the mere suggestion of patch-test placement whereas others cringe at the thought of it. It is the author’s opinion that the answer lies primarily in how contact dermatitis is learned. Many practitioners do not enjoy the subject of contact dermatitis because it is often viewed as a subject requiring memorization of hundreds of chemicals with little clinical utility. This chapter will present somewhat of a paradigm shift with regard to the approach to managing contact dermatitis. The focus will be to de-emphasize rote memorization of contact allergens, emphasizing instead the core knowledge that can be broadly applied by dermatologists to various clinical scenarios.

Contact Dermatitis: the Concept

It has been reported that 6% to 10% of all dermatology visits are as a result of contact dermatitis. Q56.1 One of the core concepts is that the term contact dermatitis is broad and is used to include allergic contact dermatitis (ACD), irritant contact dermatitis (ICD), and the much less common contact urticaria. We will only discuss ACD and ICD. Within these subgroups almost any morphologic reaction on the skin is possible. However, eczematous reactions are most common—either acute eczematous eruptions (such as poison ivy) or chronic eczematous eruptions such as typical cases of chronic hand dermatitis. The general rule of thumb is that of all cases of contact dermatitis, 80% are irritant and 20% are allergic in nature.

Q56.2 The term contact dermatitis medicamentosa is used when the allergen source is found to be a medicament (something used to treat, prevent, or alleviate the symptoms of disease).

Allergic Contact Dermatitis

ACD is a classic type IV delayed hypersensitivity reaction with a resultant inflammatory response. ACD is both patient and allergen specific. This means that a specific patient with an intact and functioning immune system exposed to a specific allergen are both required.

The term sensitizer is used in the world of contact dermatitis to refer to potential allergens capable of inducing type IV hypersensitivity in the skin. The terms ‘sensitizer’ and ‘allergen’ are often used interchangeably.

Irritant Contact Dermatitis

ICD is the normal reaction of skin to a noxious stimulus. It involves a nonspecific inflammatory response. Virtually all patients will react to a given substance if the noxious threshold for that substance is reached. The noxious threshold is a function of three factors: (1) the innate irritant properties of the substance, (2) the exposure level—determined by concentration, frequency, and duration of exposure, and (3) the degree of penetration through the stratum corneum, which is affected both by the health of the stratum corneum and the degree of occlusion. ICD does not require specific antigen sensitization.

When to Suspect Contact Dermatitis

Q56.3 Contact dermatitis should be suspected in any pruritic or painful cutaneous eruption that is refractory to conventional therapy. Although symptomatology is not specific, ACD tends to be associated with more pruritus and ICD is more likely to be reported as painful or uncomfortable. A thorough history coupled with a high index of suspicion is required in refractory, worsening, or intermittent flaring cases of dermatitis affecting any body site. Certain anatomic sites have a high incidence of contact dermatitis and should be considered to indicate a relatively high yield for patch-testing. Such sites include eyelids, lips, perioral area, neck, axilla, hands, feet, anogenital region, and lower legs. Contact dermatitis is much less likely to occur exclusively on the trunk, proximal extremities, and scalp. These latter distributions should reduce the suspicion of contact dermatitis and increase the suspicion of an endogenous dermatitis.

Regional Approach

It is both more practical and more efficacious to learn contact dermatitis in a regional manner. Although any medicament may cause contact dermatitis medicamentosa at any body site where applied, this chapter will highlight the medicaments that are likely the etiology in certain regions of the body.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here